Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - Protagonist Therapeutics, Inc | tm2035018d1_ex99-2.htm |
| 8-K - FORM 8-K - Protagonist Therapeutics, Inc | tm2035018d1_8k.htm |
Exhibit 99.1
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
-- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 --
-- PTG-300 received European Medicine Agency (EMA) Orphan Drug Designation for the treatment of polycythemia vera --
-- Company is advancing additional oral IL-23 receptor antagonists into clinical development in collaboration with Janssen --
NEWARK, Calif., November 4, 2020 -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate update.
“The three clinical assets PTG-300, PN-943 and PTG-200, all discovered through our peptide technology platform, continue to make progress in Phase 2 clinical proof-of-concept studies,” commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer. “We look forward to sharing updated clinical data in December from our Phase 2 study of PTG-300 in patients with polycythemia vera and see significant opportunity for PTG-300 to address unmet needs and improve upon the current standards of care.”
Dr. Patel continued, “We are moving forward with our ongoing Phase 2 clinical programs with the oral alpha-4-beta-7 integrin antagonist PN-943 in patients with ulcerative colitis, and the oral interleukin-23 receptor antagonist PTG-200 in patients with Crohn’s disease. In addition, we’re encouraged by the steady progress in our ongoing collaboration with Janssen, and recently announced the selection of two additional oral interleukin-23 receptor antagonists, PN-235 and PN-232, for advancement into clinical development. These candidates provide several strategic options for development in multiple indications.”
Product Development and Corporate Update
PTG-300: Subcutaneous Injectable Hepcidin Mimetic for Polycythemia Vera and Other Blood Disorders
| · | Five presentations have been accepted for the American Society for Hematology (ASH) Annual meeting, taking place in a virtual format from December 5-8, 2020. Two posters and one oral presentation are related to PTG-300 and polycythemia vera and two posters describe the hepcidin mimetic mechanism of action and a hepcidin mimetic for oral delivery. |
| · | In October, PTG-300 was granted orphan designation by the European Medicines Agency for the treatment of polycythemia vera. |
| · | Complete enrollment of 50 patients in the PTG-300 polycythemia vera study is expected in mid-2021. |
| · | A pivotal study of PTG-300 in the treatment of polycythemia vera is expected to begin in the second half of 2021 pending dialog with regulatory authorities. |
| · | An open-label proof-of-concept study of PTG-300 in patients with hereditary hemochromatosis is in progress and results are expected in 2021. |
PN-943: Oral Alpha-4-Beta-7 Integrin Antagonist for Inflammatory Bowel Disease
| · | Protagonist has dosed patients in a global, randomized, double-blind, placebo-controlled Phase 2 study (the "IDEAL Study") evaluating safety, tolerability and efficacy of PN-943 in approximately 150 patients with moderate to severe ulcerative colitis. |
| · | In light of the global COVID-19 pandemic, Protagonist has suspended guidance on a timeline for study completion. |
Oral IL-23 Receptor Antagonists (Janssen Biotech and Protagonist Collaboration)
| · | Protagonist Therapeutics and Janssen Biotech are jointly conducting the development of PTG-200 (JNJ-67864238) through completion of a Phase 2 clinical proof of concept study in the treatment of Crohn's disease. |
| · | Two additional oral peptide IL-23 receptor antagonist candidates from the collaboration agreement with Janssen Biotech, PN-235 (JNJ-77242113) and PN-232 (JNJ-75105186), have been selected for advancement into clinical development. A Phase 1 study of PN-235 is expected to begin in the fourth quarter of 2020. |
Financial Update
| · | During the third quarter of 2020, the Company issued 333,000 shares through its at-the-market (ATM) program and raised $6.4 million; shares were sold at an average price of $19.65 per share. |
| · | The Company also reported sales of an additional 918,000 shares through its ATM program during October 2020, raising $18.9 million, at an average price of $21.03 per share. |
Financial Results
| · | Cash, cash equivalents and marketable securities as of September 30, 2020, were $200.0 million. Protagonist estimates sufficient financial resources from its cash, cash equivalents, marketable securities and access to its debt facility to fund its currently planned operating and capital expenditures through mid-2023. |
| · | License and collaboration revenues were $13.1 million and $23.0 million for the three and nine months ended September 30, 2020, respectively, in comparison to $4.1 million and $(2.5) million reported for the same periods of 2019. The increase in revenue in the third quarter of 2020 compared to 2019 was related to an estimate update for services completed versus remaining services to be performed under the Janssen collaboration agreement. This revised estimate accelerated our overall performance percentage completion under the current accounting performance obligation, coupled with continued delivery of Protagonist’s services under the ongoing collaboration. The increase in year-over-year revenue was also related to a previously reported 2019 one-time cumulative adjustment related to the application of revenue recognition principles following the May 2019 amendment of the Janssen Biotech collaboration agreement that had reduced revenue by $9.4 million for the nine months ended September 30, 2019. |
| · | Research and Development (R&D) expenses for the three and nine months ended September 30, 2020, were $16.0 million and $55.0 million, respectively, as compared to $17.3 million and $49.1 million for the same periods of 2019. 2020 expenses were primarily related to advancing our clinical development including the ongoing Phase 2 clinical trial for polycythemia vera with PTG-300, PN-943 Phase 2 study in ulcerative colitis, and the IL-23 receptor antagonist research collaboration activities with Janssen Biotech. |
| · | General and Administrative (G&A) expenses for the three and nine months ended September 30, 2020, were $4.9 million and $13.6 million, respectively, as compared to $4.0 million and $11.6 million for the same periods of 2019. The increases were primarily related to professional fees, insurance costs and salary related expenses to support the growth in operations. |
| · | Net loss for the three and nine months ended September 30, 2020, was $7.8 million and $47.3 million or a net loss of $0.21 per share and $1.45 per share, respectively, as compared to a net loss of $16.4 million and $59.7 million, or a net loss of $0.61 per share and $2.36 per share, respectively, for the same periods of 2019. |
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. In addition to PTG-200, two oral peptide interleukin-23 receptor antagonist candidates from a collaboration with Janssen Biotech, Inc., are in development and have been selected for advancement into clinical studies. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential of our product candidates to improve standards of care, our ability to fund operations into future periods, and our expectations regarding the timing of the initiation of clinical trials. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen, the impact of the current COVID-19 pandemic on our discovery and development efforts, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
PROTAGONIST THERAPEUTICS, INC.
Selected Consolidated Balance Sheet Data
(In thousands)
(Unaudited)
| September 30, 2020 | December 31, 2019 | |||||||
| Cash, cash equivalents and marketable securities | $ | 199,999 | $ | 133,017 | ||||
| Working capital | 165,588 | 109,905 | ||||||
| Total assets | 217,320 | 154,917 | ||||||
| Long-term debt, net | -- | 9,794 | ||||||
| Deferred revenue - related party | 20,877 | 41,530 | ||||||
| Accumulated deficit | (264,925 | ) | (217,661 | ) | ||||
| Total stockholders’ equity | 169,590 | 79,964 | ||||||
PROTAGONIST THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations
(Amounts in thousands except share and per share data)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenue: | ||||||||||||||||
| License and collaboration revenue - related party | $ | 13,114 | $ | 4,141 | $ | 22,978 | $ | (2,488 | ) | |||||||
| Operating expenses: | ||||||||||||||||
| Research and development (1) | 15,995 | 17,293 | 55,020 | 49,092 | ||||||||||||
| General and administrative (1) | 4,891 | 4,015 | 13,644 | 11,642 | ||||||||||||
| Total operating expenses | 20,886 | 21,308 | 68,664 | 60,734 | ||||||||||||
| Loss from operations | (7,772 | ) | (17,167 | ) | (45,686 | ) | (63,222 | ) | ||||||||
| Interest income | 87 | 762 | 820 | 2,134 | ||||||||||||
| Interest expense | (19 | ) | -- | (471 | ) | -- | ||||||||||
| Loss on early repayment of debt | -- | -- | (585 | ) | -- | |||||||||||
| Other expense, net | (59 | ) | (106 | ) | (37 | ) | (145 | ) | ||||||||
| Loss before income taxes | (7,763 | ) | (16,511 | ) | (45,959 | ) | (61,233 | ) | ||||||||
| Income tax (expense) benefit | -- | 102 | (1,305 | ) | 1,547 | |||||||||||
| Net loss | $ | (7,763 | ) | $ | (16,409 | ) | $ | (47,264 | ) | $ | (59,686 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.21 | ) | $ | (0.61 | ) | $ | (1.45 | ) | $ | (2.36 | ) | ||||
| Weighted-average shares used to compute net loss per share, basic and diluted | 37,386,881 | 29,956,957 | 32,647,524 | 25,315,512 | ||||||||||||
(1)Amounts include non-cash stock-based compensation expense as follows (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| Stock-based compensation | 2020 | 2019 | 2020 | 2019 | ||||||||||||
| Research and development | $ | 1,006 | $ | 1,137 | $ | 3,098 | $ | 3,237 | ||||||||
| General and administrative | 882 | 1,064 | 2,834 | 2,956 | ||||||||||||
| Total stock-based compensation expense | $ | 1,888 | $ | 2,201 | $ | 5,932 | $ | 6,193 | ||||||||
###
Contacts:
Solebury Trout
Rich Allan (media)
Tel: +1 646-378-2958
Email: rallan@soleburytrout.com
Brian Korb (investors)
Tel: +1 646-378-2923
Email: bkorb@soleburytrout.com